Australia's Orthocell set for best week since November 2024 on US DoD approval for key product

Orthocell

17/04/2026 04:40

** Shares of Australian regenerative medicine co Orthocell OCC.AX rise 7.8% to A$1.1

** Co says first surgical case using its nerve repair device Remplir completed in U.S Department of Defense (DoD) hospital network

** Stock has risen 27.4% so far this week, set for best week since late November 2024

** On Wednesday, stock gained 24.1% in its best day in more than a year on news that co has secured approval from U.S. DoD for use of Remplir

** Stock down 6% YTD

(Reporting by Aamir Sheik Khalid in Bengaluru)

((Aamir.SheikKhalid@thomsonreuters.com))